Human Susceptibility and Resistance to Norwalk Virus Infection
Overview
Molecular Biology
Authors
Affiliations
Infectious diseases have influenced population genetics and the evolution of the structure of the human genome in part by selecting for host susceptibility alleles that modify pathogenesis. Norovirus infection is associated with approximately 90% of epidemic non-bacterial acute gastroenteritis worldwide. Here, we show that resistance to Norwalk virus infection is multifactorial. Using a human challenge model, we showed that 29% of our study population was homozygous recessive for the alpha(1,2)fucosyltransferase gene (FUT2) in the ABH histo-blood group family and did not express the H type-1 oligosaccharide ligand required for Norwalk virus binding. The FUT2 susceptibility allele was fully penetrant against Norwalk virus infection as none of these individuals developed an infection after challenge, regardless of dose. Of the susceptible population that encoded a functional FUT2 gene, a portion was resistant to infection, suggesting that a memory immune response or some other unidentified factor also affords protection from Norwalk virus infection.
Norovirus replication, host interactions and vaccine advances.
Prasad B, Atmar R, Ramani S, Palzkill T, Song Y, Crawford S Nat Rev Microbiol. 2025; .
PMID: 39824927 DOI: 10.1038/s41579-024-01144-9.
H and B Blood Antigens Are Essential for In Vitro Replication of GII.2 Human Norovirus.
Tamiya S, Matsumoto N, Kurokawa S, Nakamura Y, Takahashi Y, Sakon N Open Forum Infect Dis. 2025; 12(1):ofae714.
PMID: 39758750 PMC: 11697099. DOI: 10.1093/ofid/ofae714.
Human genetic variation reveals FCRL3 is a lymphocyte receptor for .
Keener R, Shi S, Dalapati T, Wang L, Reinoso-Vizcaino N, Luftig M bioRxiv. 2024; .
PMID: 39677730 PMC: 11643160. DOI: 10.1101/2024.12.05.626452.
Fucosylation of glycoproteins and glycolipids: opposing roles in cholera intoxication.
Ghorashi A, Boucher A, Archer-Hartmann S, Zalem D, Taherzadeh Ghahfarrokhi M, Murray N Nat Chem Biol. 2024; .
PMID: 39414978 DOI: 10.1038/s41589-024-01748-5.
Izquierdo-Lara R, Villabruna N, Hesselink D, Schapendonk C, Ribo Pons S, Nieuwenhuijse D EBioMedicine. 2024; 109:105391.
PMID: 39396425 PMC: 11663770. DOI: 10.1016/j.ebiom.2024.105391.